UNS 0.00% 0.5¢ unilife corporation

Let us not forget for a moment that this guy left BD to join AS...

  1. 1,369 Posts.
    Let us not forget for a moment that this guy left BD to join AS and the team at Unilife. FACT

    Unilife Corp ($UNIS) - Innovative Drug Delivery Device Solutions - Presentation Transcript
    Innovative Drug Delivery Device Solutions
    Ramin Mojdeh, Ph.D.
    Executive Vice President and
    Chief Operating Officer
    UBS Specialty Pharma Conference
    May 2011
    Cautionary Note Regarding Forward-Looking Statements
    This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management?s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However you should not place undue reliance on any such forward looking statements as these are subject to risks and uncertainties. Please refer to our press release and our SEC filings for more information regarding the use of forward looking statements.
    2
    Introducing Unilife
    Emerging global leader in innovative drug delivery device solutions
    Enable and enhance delivery of drugs by pharmaceutical customers
    Rapidly expanding pipeline being driven by customer needs
    Unifill? world?s only prefilled platform with integrated safety
    NASDAQ listed (UNIS) with state-of-the-art facility in York, PA
    3
    Attractive Market Trends and Opportunity
    $30B Injectable drug delivery device market in2015, 12.3%CAGR
    Large macromolecule composition of pharmaceutical pipeline
    Safety legislation and sharps management
    Devices drive patient acceptance, preference and adherence
    Emerging healthcare needs of aging global population
    Risingglobalhealthcarestandardscreatingstrongmarketpotential
    Improved outcomes and economics with use of unit-dose and ready to administer formats
    Trend to patients self-administration of injectable drugs
    Patent cliff - 30 biologics with $51B sales expire by 2015
    4
    Strategic Focus
    Innovative devicesolutionsforcommercialdrugs/biosimilars
    Integratedproprietaryprimarydrug delivery devices withvalue-addfeatures
    Target and address emerging unmet needs for pipeline drugs
    Pharmaceuticalcollaborations ? specializeddevicesfornoveldrugs
    Targethigh-endofmarketfordifferentiateddevices, highmargins
    Strategic sourcing of components
    In-house manufacturing and final assembly
    5
    Customer-Driven Technology Pipeline
    Technology pipeline developed in partnership with customers
    Directly responding to emerging customer needs including:
    Integrated primarydrugdelivery devices withvalue-addfeaturesandcustomization
    Advanced syringe systems with integrated safety and transfer mechanisms
    Dry drug reconstitution and delivery technologies
    Large-volume viscous drugs delivery technologies
    Targeted organ delivery devices
    Multi-chamber proprietary primary containers and delivery systems
    Reusable and disposable self administration device technologies
    Technology portfolio can be leveraged to develop customized device concepts according to specific customer needs
    6
    7
    Unifill ? The Leading Edge of Our Portfolio
    World?s first and only prefilled syringes with integrated safety
    Now in production
    Controlled retraction into barrel
    Needle locked after use for convenient, compact disposal
    Unifill as a Game Changer
    Primary drug delivery device with integrated safety
    Direct substitute for current prefill and safety prefill syringes
    Powerful brand differentiation
    Streamlines fill-finish and packaging process
    Optimal protection
    2.5B Units Annually
    Ancillary safety needle
    +
    Unifill Platform
    Standard Prefill Syringe
    Current Safety Syringe
    Direct Substitute
    Ancillary safety Device
    +
    Standard Prefill Syringe
    Current Safety Syringe
    8
    9
    Success in the Face of a Big Challenge
    Technologysolvesatechnicalchallengemostthoughtimpossible
    Sanofi invested $40MM for access rights to Unifill
    Ready for initial shipment in July ? well ahead of original schedule
    Current capacity of 60MM units, planned 150MM unit line extension
    10
    New Paradigm in Drug-Device Development
    Clinical Development (phase I, II, III)
    Approval
    Sales
    Patient requirements
    Drug industrialization requirements
    Customized delivery device
    Devicescustomizedtospecificrequirements ofdrugsandtargetpatients
    Collaboration with drug companies from clinical development through commercial sales
    Unique devices increasingly used to differentiate brands, optimize product lifecycles and enhance patient care
    Summary
    11
    Unilife - emerging global leader in innovative drug delivery devices
    Injectable drug delivery device market is attractive and growing fast
    Innovative, differentiated devices for pipeline drugs and biosimilars
    Developing rich portfolio of technologies driven by customer need
    Unifill: the 1st and only prefill syringe system with integrated safety
    The new drug-device paradigm is to target pipeline drugs to develop total system solutions for the pharmaceutical partner
    LaunchwithUnifill,thendrivegrowthwithsuccessive introductionsofinnovative,differentiateddevices
 
watchlist Created with Sketch. Add UNS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.